ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Zymeworks, CSPC Pharmaceutical Group and AstraZeneca side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Zymeworks×CSPC Pharmaceutical Group×AstraZeneca×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

ZymeworksCSPC Pharmaceutical GroupAstraZeneca
studies on the registry513554,197
open to participants now1170298
phase 3 studies under way164200
reach primary completion within a year255168
programswith a study of their own in two years168+3 named only119+5 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseZymeworksCSPC Pharmaceutical GroupAstraZeneca
Phase 1

Zymeworks: 1 of its 1 programs at phase 1

  1. Anti-GPC3 Antibody-drug Conjugate ZW251phase 1
100%

CSPC Pharmaceutical Group: 16 of its 68 programs at phase 1

  1. JMT206phase 1
  2. SYH2082phase 1
  3. JMT106phase 1
  4. paclitaxel cationic liposome for injectionphase 1
  5. palbociclibphase 1

and 11 more — sign in to see them all

24%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%
Phase 200%

CSPC Pharmaceutical Group: 26 of its 68 programs at phase 2

  1. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2
  2. SYS6006 COVID-19 vaccinephase 2
  3. ATM Inhibitor SYH2051phase 2
  4. SYH2069phase 2
  5. SYH2070phase 2

and 21 more — sign in to see them all

38%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%
Phase 300%

CSPC Pharmaceutical Group: 25 of its 68 programs at phase 3

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. anbenitamabphase 3

and 20 more — sign in to see them all

37%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%
Approved, new studies00%

CSPC Pharmaceutical Group: 1 of its 68 programs at approved, new studies

  1. Tenecteplaseapproved, new study
1%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Zymeworks1 readouts · 0 phase 3··········

Zymeworks, Sep ’27: 1 program whose next study reaches primary completion

  1. Anti-GPC3 Antibody-drug Conjugate ZW251phase 1 · Sep 0 · NCT07164313
·
CSPC Pharmaceutical Group39 readouts · 6 phase 3

CSPC Pharmaceutical Group, Nov ’26: 3 programs whose next study reaches primary completion

  1. SYH2061phase 1 · Nov 24 · NCT07241910
  2. Anti-EGFR Antibody-drug Conjugate CPO301phase 3 · Nov 30 · NCT07256509
  3. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2 · Nov 30 · NCT07280832

CSPC Pharmaceutical Group, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. anbenitamabphase 3 · Dec 16 · NCT06747338
  2. Docetaxelphase 3 · Dec 16 · NCT06747338
  3. glumetinibphase 3 · Dec 25 · NCT06525350
  4. paliperidoneno phase · Dec 31 · NCT07493551
  5. SYH2059phase 2 · Dec 31 · NCT07510958

and 1 more — sign in to see them all

CSPC Pharmaceutical Group, Jan ’27: 4 programs whose next study reaches primary completion

  1. SYH2056phase 1 · Jan 30 · NCT07771777
  2. SYH2082phase 1 · Jan 30 · NCT07532655
  3. SYS6005phase 1 · Jan 30 · NCT06958679
  4. SYH2062phase 2 · Jan 31 · NCT07940075

CSPC Pharmaceutical Group, Feb ’27: 4 programs whose next study reaches primary completion

  1. SYH2072phase 2 · Feb 1 · NCT07647783
  2. SYH2092phase 1 · Feb 9 · NCT07776041
  3. JMT206phase 1 · Feb 28 · NCT07840729
  4. SYS6040phase 1 · Feb 28 · NCT06970795

CSPC Pharmaceutical Group, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. A zoster mRNA vaccine SYS6017phase 2 · Mar 10 · NCT07354659
  2. becotatugphase 3 · Mar 26 · NCT06380348
  3. SYS6041phase 2 · Mar 28 · NCT07744763

CSPC Pharmaceutical Group, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. enlonstobartphase 3 · Apr 0 · NCT06136988
  2. CPO-107phase 2 · Apr 1 · NCT07029139
  3. SYHX1901phase 3 · Apr 28 · NCT06943950
  4. SYH2070phase 2 · Apr 30 · NCT07695597
  5. SYH2085phase 2 · Apr 30 · NCT07798193

CSPC Pharmaceutical Group, May ’27: 1 program whose next study reaches primary completion

  1. anbenitamab repodatecanphase 3 · May 29 · NCT07545044

CSPC Pharmaceutical Group, Jun ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. ATM Inhibitor SYH2051phase 2 · Jun 15 · NCT06775236
  2. bempedoic acidphase 3 · Jun 30 · NCT07623915

CSPC Pharmaceutical Group, Jul ’27: 4 programs whose next study reaches primary completion

  1. ocankitugphase 3 · Jul 1 · NCT07418736
  2. SYH2053phase 3 · Jul 15 · NCT07938034
  3. SYS6045phase 2 · Jul 30 · NCT07122063
  4. CHO cellphase 2 · Jul 31 · NCT07892989

CSPC Pharmaceutical Group, Aug ’27: 2 programs whose next study reaches primary completion

  1. SYHX2008phase 3 · Aug 1 · NCT06505395
  2. JMT203phase 2 · Aug 14 · NCT06868849

CSPC Pharmaceutical Group, Sep ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Aripiprazoleno phase · Sep 5 · NCT07547384
  2. SYH2069phase 2 · Sep 28 · NCT07796477
  3. Tenecteplaseapproved, new study · Sep 30 · NCT07201688

CSPC Pharmaceutical Group, Oct ’27: 2 programs whose next study reaches primary completion

  1. palbociclibphase 1 · Oct 0 · NCT06941142
  2. Sirolimusphase 3 · Oct 0 · NCT06941142
AstraZeneca61 readouts · 16 phase 3

AstraZeneca, Nov ’26: 6 programs whose next study reaches primary completion

  1. elecoglipronphase 3 · Nov 18 · NCT07723833
  2. Elecoglipron Test formulation 1 Dose Aphase 1 · Nov 18 · NCT07723833
  3. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  4. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  5. durvalumabapproved, new study · Nov 30 · NCT07081633

and 1 more — sign in to see them all

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 7 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Zymeworks

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

CSPC Pharmaceutical Group

New programs 6

  • SYH9061phase 2 · first study · Nov 2 · Idiopathic Pulmonary Fibrosis
  • SYS6062phase 2 · first study · Oct 20 · Stomach Neoplasms
  • CHO cellphase 2 · first study · Oct 19 · COVID-19
  • SYH2066phase 2 · first study · Oct 11 · Respiratory Syncytial Virus Infections
  • Generic Drugphase 3 · first study · Sep 28 · Triple Negative Breast Neoplasms
  • SYS6088phase 2 · first study · Sep 20 · Neoplasms

Reached a new phase 3

  • SYH2072phase 2 · Oct 28 · Hyperaldosteronism
  • SYH2069phase 2 · Aug 25 · Obesity
  • SYH2085phase 2 · Aug 25 · Influenza, Human

Study stopped 0

None

Primary completion later 2

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Where they overlap

Conditions where at least two of them have programs: 42 in all. A program counts in each condition its studies name most.

ConditionZymeworksCSPC Pharmaceutical GroupAstraZeneca
Carcinoma, Hepatocellularall three · compare here

Zymeworks in Carcinoma, Hepatocellular: 1 program

  1. Anti-GPC3 Antibody-drug Conjugate ZW251phase 1

Their studies: Zymeworks’ studies of Carcinoma, Hepatocellular in search

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here–

CSPC Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. glumetinibphase 3

and 5 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 18 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 13 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Breast Neoplasms: 10 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. anbenitamabphase 3
  4. Sirolimusphase 3
  5. anbenitamab repodatecanphase 3

and 5 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Breast Neoplasms in search

AstraZeneca in Breast Neoplasms: 9 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 4 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Stomach Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Stomach Neoplasms: 7 programs

  1. Docetaxelphase 3
  2. enlonstobartphase 3
  3. anbenitamabphase 3
  4. anbenitamab repodatecanphase 3
  5. trastuzumab envedotinphase 3

and 2 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Stomach Neoplasms in search

Prostatic Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Prostatic Neoplasms: 1 program

  1. Docetaxelphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Prostatic Neoplasms in search

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Asthma2 of 3 · compare here–

CSPC Pharmaceutical Group in Asthma: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Asthma in search

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Renal Insufficiency2 of 3 · compare here–

CSPC Pharmaceutical Group in Renal Insufficiency: 3 programs

  1. Sirolimusphase 3
  2. SYH2053phase 3
  3. aprocitentanphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Renal Insufficiency in search

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Neoplasms2 of 3 · compare here–

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Obesity2 of 3 · compare here–

CSPC Pharmaceutical Group in Obesity: 5 programs

  1. edaglutide alfaphase 3
  2. SYH2069phase 2
  3. SYH2082phase 1
  4. SYH2092phase 1
  5. SYH9017phase 1

Their studies: CSPC Pharmaceutical Group’s studies of Obesity in search

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here–

CSPC Pharmaceutical Group in Pulmonary Disease, Chronic Obstructive: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Pulmonary Disease, Chronic Obstructive in search

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here–

CSPC Pharmaceutical Group in Squamous Cell Carcinoma of Head and Neck: 4 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. becotatugphase 3
  3. Sutantatug Envedotinphase 3
  4. palbociclibphase 1

Their studies: CSPC Pharmaceutical Group’s studies of Squamous Cell Carcinoma of Head and Neck in search

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 5 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. volrustomigphase 3
  4. monalizumabphase 3
  5. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

Diabetes Mellitus, Type 22 of 3 · compare here–

CSPC Pharmaceutical Group in Diabetes Mellitus, Type 2: 2 programs

  1. edaglutide alfaphase 3
  2. SYH2069phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Colorectal Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Colorectal Neoplasms: 4 programs

  1. becotatugphase 3
  2. anbenitamab repodatecanphase 3
  3. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2
  4. sintilimabphase 2

Their studies: CSPC Pharmaceutical Group’s studies of Colorectal Neoplasms in search

AstraZeneca in Colorectal Neoplasms: 2 programs

  1. Actinium-225phase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Ovarian Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Ovarian Neoplasms: 4 programs

  1. enlonstobartphase 3
  2. anbenitamab repodatecanphase 3
  3. trastuzumab envedotinphase 3
  4. SYS6041phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Ovarian Neoplasms in search

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

Triple Negative Breast Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Triple Negative Breast Neoplasms: 2 programs

  1. Albumin-Bound Paclitaxelphase 3
  2. Generic Drugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Triple Negative Breast Neoplasms in search

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

Hyperlipidemias2 of 3 · compare here–

CSPC Pharmaceutical Group in Hyperlipidemias: 2 programs

  1. SYH2053phase 3
  2. bempedoic acidphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Hyperlipidemias in search

AstraZeneca in Hyperlipidemias: 3 programs

  1. laroprovstatphase 3
  2. Laroprovstat/ezetimibe FCDP-slow variantphase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hyperlipidemias in search

Melanoma2 of 3 · compare here–

CSPC Pharmaceutical Group in Melanoma: 2 programs

  1. Albumin-Bound Paclitaxelphase 3
  2. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Melanoma in search

AstraZeneca in Melanoma: 3 programs

  1. tremelimumabphase 3
  2. ceralasertibphase 3
  3. CD8-guided IL-2 Fusion Protein AZD6750phase 2

Their studies: AstraZeneca’s studies of Melanoma in search

Carcinoma, Renal Cell2 of 3 · compare here–

CSPC Pharmaceutical Group in Carcinoma, Renal Cell: 1 program

  1. palbociclibphase 1

Their studies: CSPC Pharmaceutical Group’s studies of Carcinoma, Renal Cell in search

AstraZeneca in Carcinoma, Renal Cell: 3 programs

  1. volrustomigphase 3
  2. Actinium-225phase 3
  3. casdatifanphase 1

Their studies: AstraZeneca’s studies of Carcinoma, Renal Cell in search

COVID-192 of 3 · compare here–

CSPC Pharmaceutical Group in COVID-19: 3 programs

  1. SYS6006 COVID-19 vaccinephase 2
  2. CHO cellphase 2
  3. palbociclibphase 1

Their studies: CSPC Pharmaceutical Group’s studies of COVID-19 in search

AstraZeneca in COVID-19: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of COVID-19 in search

Dyslipidemias2 of 3 · compare here–

CSPC Pharmaceutical Group in Dyslipidemias: 1 program

  1. bempedoic acidphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Dyslipidemias in search

AstraZeneca in Dyslipidemias: 3 programs

  1. laroprovstatphase 3
  2. AZD4954phase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Dyslipidemias in search

Hypertension2 of 3 · compare here–

CSPC Pharmaceutical Group in Hypertension: 2 programs

  1. aprocitentanphase 3
  2. SYH2072phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Hypertension in search

AstraZeneca in Hypertension: 2 programs

  1. baxdrostatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypertension in search

Lymphoma, B-Cell2 of 3 · compare here–

CSPC Pharmaceutical Group in Lymphoma, B-Cell: 1 program

  1. CPO-107phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Lymphoma, B-Cell in search

Neoplasm Metastasis2 of 3 · compare here–

CSPC Pharmaceutical Group in Neoplasm Metastasis: 1 program

  1. paclitaxel cationic liposome for injectionphase 1

Their studies: CSPC Pharmaceutical Group’s studies of Neoplasm Metastasis in search

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Pancreatic Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Pancreatic Neoplasms: 1 program

  1. Albumin-Bound Paclitaxelphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Pancreatic Neoplasms in search

AstraZeneca in Pancreatic Neoplasms: 3 programs

  1. sonesitatug vedotinphase 3
  2. Leucovorinphase 2
  3. Pan-KRAS Inhibitor JAB-23E73phase 2

Their studies: AstraZeneca’s studies of Pancreatic Neoplasms in search

Glomerulonephritis, Membranous2 of 3 · compare here–

CSPC Pharmaceutical Group in Glomerulonephritis, Membranous: 1 program

  1. CPO-107phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Glomerulonephritis, Membranous in search

AstraZeneca in Glomerulonephritis, Membranous: 2 programs

  1. surovatamigphase 3
  2. ALXN1920phase 2

Their studies: AstraZeneca’s studies of Glomerulonephritis, Membranous in search

Hypercholesterolemia2 of 3 · compare here–

CSPC Pharmaceutical Group in Hypercholesterolemia: 1 program

  1. bempedoic acidphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Hypercholesterolemia in search

AstraZeneca in Hypercholesterolemia: 2 programs

  1. laroprovstatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypercholesterolemia in search

Idiopathic Pulmonary Fibrosis2 of 3 · compare here–

CSPC Pharmaceutical Group in Idiopathic Pulmonary Fibrosis: 2 programs

  1. SYH2059phase 2
  2. SYH9061phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Idiopathic Pulmonary Fibrosis in search

AstraZeneca in Idiopathic Pulmonary Fibrosis: 1 program

  1. AZD8965phase 2

Their studies: AstraZeneca’s studies of Idiopathic Pulmonary Fibrosis in search

Influenza, Human2 of 3 · compare here–

CSPC Pharmaceutical Group in Influenza, Human: 1 program

  1. SYH2085phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Influenza, Human in search

AstraZeneca in Influenza, Human: 2 programs

  1. AZD4117phase 2
  2. AZD5315phase 2

Their studies: AstraZeneca’s studies of Influenza, Human in search

Kidney Failure, Chronic2 of 3 · compare here–

CSPC Pharmaceutical Group in Kidney Failure, Chronic: 2 programs

  1. Sirolimusphase 3
  2. CHO cellphase 2

Their studies: CSPC Pharmaceutical Group’s studies of Kidney Failure, Chronic in search

AstraZeneca in Kidney Failure, Chronic: 1 program

  1. Berzanoflastphase 2

Their studies: AstraZeneca’s studies of Kidney Failure, Chronic in search

Nasal Polyps2 of 3 · compare here–

CSPC Pharmaceutical Group in Nasal Polyps: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Nasal Polyps in search

AstraZeneca in Nasal Polyps: 2 programs

  1. tezepelumabapproved, new study
  2. benralizumabapproved, new study

Their studies: AstraZeneca’s studies of Nasal Polyps in search

Small Cell Lung Carcinoma2 of 3 · compare here–

CSPC Pharmaceutical Group in Small Cell Lung Carcinoma: 1 program

  1. SYS6040phase 1

Their studies: CSPC Pharmaceutical Group’s studies of Small Cell Lung Carcinoma in search

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Uterine Cervical Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Uterine Cervical Neoplasms: 2 programs

  1. enlonstobartphase 3
  2. Sutantatug Envedotinphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Uterine Cervical Neoplasms in search

AstraZeneca in Uterine Cervical Neoplasms: 1 program

  1. volrustomigphase 3

Their studies: AstraZeneca’s studies of Uterine Cervical Neoplasms in search

Acromegaly2 of 3 · compare here–

CSPC Pharmaceutical Group in Acromegaly: 1 program

  1. SYHX2008phase 3

Their studies: CSPC Pharmaceutical Group’s studies of Acromegaly in search

AstraZeneca in Acromegaly: 1 program

  1. ALXN2420phase 2

Their studies: AstraZeneca’s studies of Acromegaly in search

Coronary Artery Disease2 of 3 · compare here–

CSPC Pharmaceutical Group in Coronary Artery Disease: 1 program

  1. bempedoic acidphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Coronary Artery Disease in search

AstraZeneca in Coronary Artery Disease: 1 program

  1. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Coronary Artery Disease in search

Dermatitis, Atopic2 of 3 · compare here–

CSPC Pharmaceutical Group in Dermatitis, Atopic: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Dermatitis, Atopic in search

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

Diabetes Mellitus2 of 3 · compare here–

CSPC Pharmaceutical Group in Diabetes Mellitus: 1 program

  1. edaglutide alfaphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Diabetes Mellitus in search

AstraZeneca in Diabetes Mellitus: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus in search

Fallopian Tube Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Fallopian Tube Neoplasms: 1 program

  1. Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043phase 3

Their studies: CSPC Pharmaceutical Group’s studies of Fallopian Tube Neoplasms in search

AstraZeneca in Fallopian Tube Neoplasms: 1 program

  1. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Fallopian Tube Neoplasms in search

Head and Neck Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Head and Neck Neoplasms: 1 program

  1. ATM Inhibitor SYH2051phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Head and Neck Neoplasms in search

AstraZeneca in Head and Neck Neoplasms: 1 program

  1. monalizumabphase 3

Their studies: AstraZeneca’s studies of Head and Neck Neoplasms in search

Hyperaldosteronism2 of 3 · compare here–

CSPC Pharmaceutical Group in Hyperaldosteronism: 1 program

  1. SYH2072phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Hyperaldosteronism in search

AstraZeneca in Hyperaldosteronism: 1 program

  1. baxdrostatphase 3

Their studies: AstraZeneca’s studies of Hyperaldosteronism in search

Liver Diseases2 of 3 · compare here–

CSPC Pharmaceutical Group in Liver Diseases: 1 program

  1. aprocitentanphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Liver Diseases in search

AstraZeneca in Liver Diseases: 1 program

  1. AZD2389phase 2

Their studies: AstraZeneca’s studies of Liver Diseases in search

Lung Neoplasms2 of 3 · compare here–

CSPC Pharmaceutical Group in Lung Neoplasms: 1 program

  1. Docetaxelphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Lung Neoplasms in search

AstraZeneca in Lung Neoplasms: 1 program

  1. osimertinibapproved, new study

Their studies: AstraZeneca’s studies of Lung Neoplasms in search

Respiratory Syncytial Virus Infections2 of 3 · compare here–

CSPC Pharmaceutical Group in Respiratory Syncytial Virus Infections: 1 program

  1. SYH2066phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Respiratory Syncytial Virus Infections in search

AstraZeneca in Respiratory Syncytial Virus Infections: 1 program

  1. Palivizumabapproved, new study

Their studies: AstraZeneca’s studies of Respiratory Syncytial Virus Infections in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Zymeworks 1 of 1 · CSPC Pharmaceutical Group 25 of 68 · AstraZeneca 68 of 119 programs (45 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (CSPC Pharmaceutical Group: 3, AstraZeneca: 5).